Skip to main content

Rheumatology training and research in Iran

Rheumatology International volume 39, pages 1307–1319 (2019)Cite this article

Abstract

Rheumatology is one of the most important clinical subspecialties in Iran. In the past 2 decades, Iran has witnessed an immense progress in the field of rheumatology training and research, which has led to an increase in the number of rheumatologists and research performed in the field of musculoskeletal disorders. These advances have made way for greater access to subspecialty care for rheumatic disorders. To write this article, we performed a systematic literature search using PubMed/MEDLINE, Web of Science, SCOPUS, Google Scholar and SID databases. In the first part of the manuscript, we will provide information about the history of rheumatology, rheumatology practice, referral system, the rheumatology training in medical schools, training of rheumatology subspecialists and post-graduate program of continuing medical education for rheumatologists in Iran as well as the Iranian Rheumatology Society. We will then focus on rheumatology research, top researchers, research centers focused on rheumatic disorders, the characteristics of common rheumatic diseases and ultimately biologics and biosimilars in Iran.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Davatchi F, Jamshidi AR, Banihashemi AT et al (2008) WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol 35(7):1384

    PubMed  Google Scholar 

  2. Davatchi F, Sandoughi M, Moghimi N et al (2016) Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. Int J Rheum Dis 19(11):1056–1062. https://doi.org/10.1111/1756-185X.12809

    Article  PubMed  Google Scholar 

  3. Irani AD, Poorolajal J, Khalilian A, Esmailnasab N, Cheraghi Z (2013) Prevalence of osteoporosis in Iran: a meta-analysis. J Res Med Sci 18(9):759–766

    PubMed  PubMed Central  Google Scholar 

  4. Naghavi M, Abolhassani F, Pourmalek F et al (2009) The burden of disease and injury in Iran in the year 2003. Popul Health Metr 4(1):1–19. https://doi.org/10.1186/1478-7954-7-9

    Article  Google Scholar 

  5. Ministry of Health and Medical Education. Deputy of Education. http://dme.behdasht.gov.ir/index.aspx. Last updated 9 May 2019. Accessed 10 May 2019

  6. Davatchi Fereydoun (2009) Rheumatology in Iran. Int J Rheum Dis 12:283–287. https://doi.org/10.1111/j.1756-185X.2009.01425.x

    Article  PubMed  Google Scholar 

  7. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3

    Article  PubMed  Google Scholar 

  8. Iranian Rheumatology Association. About-us. http://iranianra.ir/page/142/About-us. Last updated 9 May 2019. Accessed 10 May 2019

  9. Rheumatology Research Center. http://rrc.tums.ac.ir/page/view/id/3?lang=fa. Last updated 9 May 2019. Accessed 10 May 2019

  10. Continuing Medical Education. http://cehp.behdasht.gov.ir/index.aspx. Last updated 9 May 2019. Accessed 10 May 2019

  11. Scientology system of faculty members. http://isid.research.ac.ir. Last updated 9 May 2019. Accessed 10 May 2019

  12. Tehran University of Medical Sciences. History of School of Medicine. http://medicine.tums.ac.ir/college/fa. Last updated 10 May 2019. Accessed 10 May 2019

  13. Ministry of Health and Medical Education. Food and Drug Administration. Biologic medications. http://fda.gov.ir. Last updated 30 Apr 2018. Accessed 10 May 2019

  14. Deshpande S (2014) History of rheumatology. Med J Dr. D.Y. Patil Univ 7(2):119–123. https://doi.org/10.4103/0975-2870.126307

  15. Tehran University Medical Journal. TUMS Publications. http://tumj.tums.ac.ir. Last updated 10 May 2019. Accessed 10 May 2019

  16. Tabriz University of Medical Sciences. History. https://www.tbzmed.ac.ir/?PageID=111. Last updated 9 May 2019. Accessed 10 May 2019

  17. Wikipedia. Tabriz University of Medical Sciences. https://en.wikipedia.org/wiki/Tabriz_University_of_Medical_Sciences. Last updated 28 Nov 2018. Accessed 10 May 2019

  18. Moghimi N, Davatchi F, Rahimi E et al (2015) WHO-ILAR COPCORD study (stage 1, urban study) in Sanandaj, Iran. Clin Rheumatol 34(3):535–543. https://doi.org/10.1007/s10067-013-2430-0

    Article  PubMed  Google Scholar 

  19. Sandoughi M, Zakeri Z, Tehrani Banihashemi A et al (2013) Prevalence of musculoskeletal disorders in southeastern Iran: a WHO-ILAR COPCORD study (stage 1, urban study). Int J Rheum Dis 16(5):509–517. https://doi.org/10.1111/1756-185X.12110

    Article  PubMed  Google Scholar 

  20. Davatchi F, Tehrani Banihashemi A, Gholami J et al (2009) The prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 28(11):1267–1274. https://doi.org/10.1007/s10067-009-1234-8

    Article  PubMed  Google Scholar 

  21. SCOPUS. Advanced search. https://www.scopus.com/search/form.uri?display=basic. Last updated 10 May 2019. Accessed 10 May 2019

  22. Kolahi S, Khabbazi A, Malek Mahdavi A et al (2017) Prevalence of musculoskeletal disorders in Azar cohort population in Northwest of Iran. Rheumatol Int 37(4):495–502. https://doi.org/10.1007/s00296-017-3661-1

    Article  PubMed  Google Scholar 

  23. Dahaghin S, Tehrani-Banihashemi SA, Faezi ST, Jamshidi AR, Davatchi F (2009) Squatting, sitting on the floor, or cycling: are life-long daily activities risk factors for clinical knee osteoarthritis? Stage III results of a community-based study. Arthritis Rheum 61(10):1337–1342. https://doi.org/10.1002/art.24737

    CAS  Article  PubMed  Google Scholar 

  24. Panah SH, Baharlouie H, Rezaeian ZS, Hawker G (2016) Cross-cultural adaptation and validation of the Persian version of the Intermittent and Constant Osteoarthritis Pain Measure for the knee. Iran J Nurs Midwifery Res 21(4):417–423. https://doi.org/10.4103/1735-9066.185595

    Article  PubMed  PubMed Central  Google Scholar 

  25. Askary-Ashtiani AR, Mousavi SJ, Montazeri A, Shamsollahi S, Parnianpour M (2009) Cultural adaptation and validation of the Persian version of the Arthritis Impact Measurement Scales 2-Short Form in patients with osteoarthritis of the knee. Disabil Rehabil 31(25):2081–2087. https://doi.org/10.3109/09638280902918746

    Article  PubMed  Google Scholar 

  26. Kordi Yoosefinejad A, Motealleh A, Babakhani M (2017) Evaluation of validity and reliability of the Persian version of the functional index of hand osteoarthritis. Rheumatol Int 37(5):719–725. https://doi.org/10.1007/s00296-016-3645-6

    Article  PubMed  Google Scholar 

  27. Salavati M, Akhbari B, Mohammadi F, Mazaheri M, Khorrami M (2011) Knee injury and Osteoarthritis Outcome Score (KOOS); reliability and validity in competitive athletes after anterior cruciate ligament reconstruction. Osteoarthr Cartil 19(4):406–410. https://doi.org/10.1016/j.joca.2011.01.010

    CAS  Article  Google Scholar 

  28. Mousavi SJ, Parnianpour M, Askary-Ashtiani AR, Hadian MR, Rostamian A, Montazeri A (2009) Translation and validation study of the Persian version of the Arthritis Impact Measurement Scales 2 (AIMS2) in patients with osteoarthritis of the knee. BMC Musculoskelet Disord 10:95. https://doi.org/10.1186/1471-2474-10-95

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nadrian H, Moghimi N, Nadrian E, Moradzadeh R, Bahmanpour K, Iranpour A, Bellamy N (2012) Validity and reliability of the Persian versions of WOMAC Osteoarthritis Index and Lequesne Algofunctional Index. Clin Rheumatol 31(7):1097–1102. https://doi.org/10.1007/s10067-012-1983-7

    Article  PubMed  Google Scholar 

  30. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A (2016) Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res 28(11):1625–1631. https://doi.org/10.1002/ptr.5174

    CAS  Article  Google Scholar 

  31. Maghsoumi-Norouzabad L, Alipoor B, Abed R, Eftekhar Sadat B, Mesgari-Abbasi M, Asghari Jafarabadi M (2016) Effects of Arctium lappa L. (Burdock) root tea on inflammatory status and oxidative stress in patients with knee osteoarthritis. Int J Rheum Dis 19(3):255–261. https://doi.org/10.1111/1756-185X.12477

    CAS  Article  PubMed  Google Scholar 

  32. Shoara R, Hashempur MH, Ashraf A, Salehi A, Dehshahri S, Habibagahi Z (2015) Efficacy and safety of topical Matricaria chamomilla L. (chamomile) oil for knee osteoarthritis: a randomized controlled clinical trial. Complement Ther Clin Pract 21(3):181–187. https://doi.org/10.1016/j.ctcp.2015.06.003

    Article  PubMed  Google Scholar 

  33. Panahi Y, Alishiri GH, Bayat N, Hosseini SM, Sahebkar A (2016) Efficacy of Elaeagnus angustifolia extract in the treatment of knee osteoarthritis: a randomized controlled trial. EXCLI J 15:203–210. https://doi.org/10.17179/excli2015-639

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hashempur MH, Sadrneshin S, Mosavat SH, Ashraf A (2018) Green tea (Camellia sinensis) for patients with knee osteoarthritis: a randomized open-label active-controlled clinical trial. Clin Nutr 37(1):85–90. https://doi.org/10.1016/j.clnu.2016.12.004

    CAS  Article  PubMed  Google Scholar 

  35. Abolhassanzadeh Z, Aflaki E, Yousefi G, Mohagheghzadeh A (2015) Randomized clinical trial of peganum oil for knee osteoarthritis. J Evid Based Complementary Altern Med 20(2):126–131. https://doi.org/10.1177/2156587214566867

    CAS  Article  PubMed  Google Scholar 

  36. Ghoochani N, Karandish M, Mowla K, Haghighizadeh MH, Jalali MT (2016) The effect of pomegranate juice on clinical signs, matrix metalloproteinases and antioxidant status in patients with knee osteoarthritis. J Sci Food Agric 96(13):4377–4381. https://doi.org/10.1002/jsfa.7647

    CAS  Article  PubMed  Google Scholar 

  37. Hashemipour S, Larijani B, Adibi H et al (2004) Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 25(4):38. https://doi.org/10.1186/1471-2458-4-38

    Article  Google Scholar 

  38. Rahnavard Z, Eybpoosh S, Homami MR et al (2010) Vitamin d deficiency in healthy male population: results of the Iranian multi- center osteoporosis study. Iran J Public Health 39(3):45–52

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Keramat A, Larigani B, Adibi H (2012) Risk factors for spinal osteoporosis as compared with femoral osteoporosis in urban Iranian women. Iran J Public Health 41(10):52–59

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Ahmadzadeh A, Emam M, Rajaei A, Moslemizadeh M, Jalessi M (2014) Comparison of three different osteoporosis risk assessment tools: ORAI (osteoporosis risk assessment instrument), SCORE (simple calculated osteoporosis risk estimation) and OST (osteoporosis self-assessment tool). Med J Islam Repub Iran 15(28):94

    Google Scholar 

  41. Ebadifardazar AA, Rezapour A, Alipour V, Sarabi-Asiabar A, Gray S, Mobinizadeh M, Yousefvand M, Arabloo J (2017) Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran. Med J Islam Repub Iran 31:39. https://doi.org/10.14196/mjiri.31.39

    Article  Google Scholar 

  42. Hajalilou M, Noshad H, Khabbazi AR, Kolahi S, Azari MH, Abbasneghad M (2012) Familial rheumatoid arthritis in patients referred to rheumatology clinics of Tabriz, Iran. Int J Rheum Dis 15(1):110–115. https://doi.org/10.1111/j.1756-185x.2011.01664.x

    Article  PubMed  Google Scholar 

  43. Korani S, Korani M, Butler AE, Sahebkar A (2019) Genetics and rheumatoid arthritis susceptibility in Iran. J Cell Physiol 234(5):5578–5587. https://doi.org/10.1002/jcp.27379

    CAS  Article  PubMed  Google Scholar 

  44. Ghamarzad Shishavan N, Pirouzpanah P, Hajialilo M et al (2016) Risk factors of rheumatoid arthritis development among females in north-west of Iran: a case–control study. Iran Red Crescent Med J 18(12):e26874. https://doi.org/10.5812/ircmj.26874

    Article  Google Scholar 

  45. Davatchi F, Abari IS, Soroosh S, Soroosh M, Sadeghi Abdollahi B (2012) Performance of the 2010 rheumatoid arthritis classification criteria. Int J Rheum Dis 15(5):455–461. https://doi.org/10.1111/j.1756-185X.2012.01766.x

    Article  PubMed  Google Scholar 

  46. Davatchi F, Akbarian M, Shahram F, Nadji A, Gharibdoost F, Jamshidi AR (2006) DMARD combination therapy in rheumatoid arthritis: 5-year follow-up results in a daily practice setting. APLAR J Rheumatol 9:60–63. https://doi.org/10.1111/j.1479-8077.2006.00166.x

    Article  Google Scholar 

  47. Khabbazi A, Kolahi S, Dastgiri S et al (2014) Safety of less frequent monitoring of liver transaminases levels in rheumatic patients treated with low-dose methotrexate. Int J Rheum Dis 17(6):646–652. https://doi.org/10.1111/1756-185X.12416

    CAS  Article  PubMed  Google Scholar 

  48. Hajiabbasi A, Shenavar Masooleh I, Alizadeh Y, Banikarimi AS, Ghavidel Parsa P (2016) Secondary Sjogren’s syndrome in 83 patients with rheumatoid arthritis. Acta Med Iran 54(7):448–453

    PubMed  Google Scholar 

  49. Shakeri A, Bazzaz MB, Khabbazi A, Fouladi RF (2011) Common carotid intima–media thickness in patients with late rheumatoid arthritis: what is the role of gender? Pak J Biol Sci 14(16):812–816

    CAS  Article  Google Scholar 

  50. Hajialilo M, Ghorbanihaghjo A, Khabbazi A, Kolahi S, Rashtchizadeh N (2014) Ankylosing spondylitis in Iran; late diagnosis and its causes. Iran Red Crescent Med J 16(4):e11798. https://doi.org/10.5812/ircmj.11798

    Article  PubMed  PubMed Central  Google Scholar 

  51. Jamshidi AR, Shahlaee A, Farhadi E, Fallahi S et al (2014) Clinical characteristics and medical management of Iranian patients with ankylosing spondylitis. Mod Rheumatol 24(3):499–504. https://doi.org/10.3109/14397595.2013.844302

    Article  PubMed  Google Scholar 

  52. Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A (2008) The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med 11(2):162–165

    PubMed  Google Scholar 

  53. Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR, Davatchi F (2009) Different aspects of psoriasis: analysis of 150 Iranian patients. Arch Iran Med 12(3):279–283

    PubMed  Google Scholar 

  54. Akbarian M, Faezi ST, Gharibdoost F et al (2010) Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. Int J Rheum Dis 13(4):374–379. https://doi.org/10.1111/j.1756-185X.2010.01547.x

    Article  PubMed  Google Scholar 

  55. Nazarinia MA, Ghaffarpasand F, Shamsdin A, Karimi AA, Abbasi N, Amiri A (2008) Systemic lupus erythematosus in the Fars Province of Iran. Lupus 17(3):221–227. https://doi.org/10.1177/0961203307086509

    CAS  Article  PubMed  Google Scholar 

  56. Espandar G, Moghimi J, Ghorbani R, Pourazizi M, Seiri MA, Khosravi S (2016) Retinal toxicity in patients treated with hydroxychloroquine: a cross-sectional study. Med Hypothesis Discov Innov Ophthalmol 5(2):41–46

    PubMed  PubMed Central  Google Scholar 

  57. Hajialiloa M, Ghorbanihaghjo A, Khabbazia A (2014) Nasal carriage rate of Staphylococcus aureus among patients with systemic lupus erythematosus and its correlation with disease relapse. Egypt Rheumatol 37(2):81–84. https://doi.org/10.1016/j.ejr.2014.06.006

    Article  Google Scholar 

  58. Gadakchi L, Hajialilo M, Nakhjavani MR et al (2018) Efficacy and safety of mycophenolate mofetil versus intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritis. Iran J Kidney Dis 12(5):288–292

    PubMed  Google Scholar 

  59. Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A (2018) Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. Mod Rheumatol 28(3):523–529. https://doi.org/10.1080/14397595.2017.1352479

    CAS  Article  PubMed  Google Scholar 

  60. Pakfetrat M, Malekmakan L, Kamranpour M, Tadayon T (2017) A five consecutive years’ study of renal function outcome among biopsy proven lupus nephritis patients in Southern Iran. Lupus 26(10):1082–1088. https://doi.org/10.1177/0961203317696588

    CAS  Article  PubMed  Google Scholar 

  61. Ghafari A, Etemadi J, Ardalan MR (2008) Renal transplantation in patients with lupus nephritis: a single-center experience. Transpl Proc 40(1):143–144. https://doi.org/10.1016/j.transproceed.2007.12.013

    CAS  Article  Google Scholar 

  62. González-Serna D, López-Isac E, Yilmaz N et al (2019) Analysis of the genetic component of systemic sclerosis in Iranian and Turkish populations through a genome-wide association study. Rheumatology (Oxford) 58(2):289–298. https://doi.org/10.1093/rheumatology/key281

    Article  Google Scholar 

  63. Yousefi B, Mahmoudi M, Sarafnejad A et al (2017) Downregulation of Aquaporin3 in systemic sclerosis dermal fibroblasts. Iran J Allergy Asthma Immunol 16(3):228–234

    PubMed  Google Scholar 

  64. Dashti N, Mahmoudi M, Gharibdoost F et al (2018) Evaluation of ITGB2 (CD18) and SELL (CD62L) genes expression and methylation of ITGB2 promoter region in patients with systemic sclerosis. Rheumatol Int 38(3):489–498. https://doi.org/10.1007/s00296-017-3915-y

    CAS  Article  PubMed  Google Scholar 

  65. Nazarinia MA, Esmaeilzadeh E, Emami Y, Salehi A (2016) One decade distinct features, morbidity and mortality of scleroderma: a cross-sectional study. Clin Exp Rheumatol 100(5):74–78

    Google Scholar 

  66. Poormoghim H, Andalib E, Jalali A, Ghaderi A, Ghorbannia A, Mojtabavi N (2016) Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran. Rheumatol Int 36(7):925–934. https://doi.org/10.1007/s00296-016-3475-6

    Article  PubMed  Google Scholar 

  67. Hajialilo M, Ghorbanihaghjo A, Khabbazi A et al (2018) Long-term follow-up of 76 Iranian patients with idiopathic inflammatory myopathies. Int J Rheum Dis 21(8):1627–1633. https://doi.org/10.1111/1756-185X.13352

    Article  PubMed  Google Scholar 

  68. Naji P, Shahram F, Nadji A, Davatchi F (2010) Effect of early treatment in polymyositis and dermatomyositis. Neurol India 58(1):58–61. https://doi.org/10.4103/0028-3886.60398

    Article  PubMed  Google Scholar 

  69. Davatchi F, Jamshidi AR, Tehrani Banihashemi A (2009) Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. Clin Rheumatol 28(11):1275–1282. https://doi.org/10.1007/s10067-009-1235-7

    Article  PubMed  Google Scholar 

  70. Alipour S, Nouri M, Sakhinia E et al (2017) Epigenetic alterations in chronic disease focusing on Behcet’s disease: review. Biomed Pharmacother 91:526–533. https://doi.org/10.1016/j.biopha.2017.04.106

    CAS  Article  PubMed  Google Scholar 

  71. Xavier JM, Davatchi F, Abade O et al (2015) Characterization of the major histocompatibility complex locus association with Behcet’s disease in Iran. Arthritis Res Ther 19(17):81. https://doi.org/10.1186/s13075-015-0585-6

    CAS  Article  Google Scholar 

  72. Xavier JM, Shahram F, Davatchi F et al (2012) Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet’s disease. Arthritis Rheum 64(8):2761–2772. https://doi.org/10.1002/art.34437

    CAS  Article  PubMed  Google Scholar 

  73. Esmaeili M, Bonyadi M, Khabbazi A et al (2011) Common MEFV mutations in Iranian Azeri Turkish patients with Behçet’s disease. Scand J Rheumatol 40(5):383–386. https://doi.org/10.3109/03009742.2011.562532

    CAS  Article  PubMed  Google Scholar 

  74. Hosseini A, Shanehbandi D, Estiar MA et al (2015) A single nucleotide polymorphism in the FOXP3 gene associated with Behcet’s disease in an Iranian population. Clin Lab 61(12):1897–1903

    CAS  PubMed  Google Scholar 

  75. Afkari B, Babaloo Z, Dolati S et al (2018) Molecular analysis of interleukin-10 gene polymorphisms in patients with Behcet’s disease. Immunol Lett 194:56–61. https://doi.org/10.1016/j.imlet.2017.12.008

    CAS  Article  PubMed  Google Scholar 

  76. Alipour S, Sakhinia E, Khabbazi A et al (2018) Methylation status of interleukin-6 gene promoter in patients with Behcet’s disease. Rheumatol Clin. https://doi.org/10.1016/j.reuma.2018.06.006

    Article  Google Scholar 

  77. Alipour S, Nouri M, Khabbazi A et al (2018) Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Behcet’s disease. J Cell Biochem 119(8):6614–6622. https://doi.org/10.1002/jcb.26809

    CAS  Article  PubMed  Google Scholar 

  78. Kolahi S, Farajzadeh MJ, Alipour S et al (2018) Determination of mir-155 and mir-146a expression rates and its association with expression level of TNF-α and CTLA4 genes in patients with Behcet’s disease. Immunol Lett 204:55–59. https://doi.org/10.1016/j.imlet.2018.10.012

    CAS  Article  PubMed  Google Scholar 

  79. Ahmadi M, Yousefi M, Abbaspour-Aghdam S et al (2019) Disturbed Th17/Treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet’s disease. J Cell Physiol 234(4):3985–3994. https://doi.org/10.1002/jcp.27207

    CAS  Article  PubMed  Google Scholar 

  80. Khabbazi A, Rashtchizadeh N, Ghorbanihaghjo A et al (2014) The status of serum vitamin D in patients with active Behcet’s disease compared with controls. Int J Rheum Dis 17(4):430–434. https://doi.org/10.1111/1756-185X.12153

    CAS  Article  PubMed  Google Scholar 

  81. Kolahi S, Khabbazi A, Khodadadi H et al (2015) Vitamin D receptor gene polymorphisms in Iranian Azary patients with Behcet’s disease. Scand J Rheumatol 44(2):163–167. https://doi.org/10.3109/03009742.2014.945477

    CAS  Article  PubMed  Google Scholar 

  82. Malek Mahdavi A, Khabbazi A, Yaaghoobian B et al (2018) Cigarette smoking and risk of Behcet’s disease: a propensity score matching analysis. Mod Rheumatol 29:1–7. https://doi.org/10.1080/14397595.2018.1493065

    Article  Google Scholar 

  83. Davatchi F, Shahram F, Chams-Davatchi C et al (2018) Behcet’s disease in Iran: analysis of 7641 cases. Mod Rheumatol 17:1–8. https://doi.org/10.1080/14397595.2018.1558752

    Article  Google Scholar 

  84. Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajialiloo M, Kolahi S (2018) Demographic and clinical features of Behcet’s disease in Azerbaijan. Int J Rheum Dis 21(5):1114–1119. https://doi.org/10.1111/1756-185x.12512

    CAS  Article  PubMed  Google Scholar 

  85. Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F (2009) Comparison of existing disease activity indices in the follow-up of patients with Behcet’s disease. Mod Rheumatol 19(5):536–541. https://doi.org/10.1007/s10165-009-0191-z

    Article  PubMed  Google Scholar 

  86. International Team for the Revision of the International Criteria for Behcet’s Disease (ITR-ICBD) (2014) The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347. https://doi.org/10.1111/jdv.12107

    Article  Google Scholar 

  87. Davatchi F, Abdollahi BS, Chams-Davatchi C et al (2015) Validation of the revised International Criteria for Behcet’s Disease (ICBD) in Iran. Clin Rheumatol 34(2):315–320. https://doi.org/10.1007/s10067-013-2411-3

    Article  PubMed  Google Scholar 

  88. Delnabi L, Gojazadeh M, Hajialilo M, Ebrahimi A, Khabbazi A (2017) Comparison of International Study Group Criteria and International Criteria for Behcet’s Disease in the Azeri population of Iran. J Anal Res Clin Med 5(3):82–85. https://doi.org/10.15171/jarcm.2017.016

    Article  Google Scholar 

  89. Davatchi F, Shahram F, Chams-Davatchi C et al (2010) Behcet’s disease: from East to West. Clin Rheumatol 29(8):823–833. https://doi.org/10.1007/s10067-010-1430-6

    Article  PubMed  Google Scholar 

  90. Davatchi F, Sadeghi Abdollahi B et al (2014) Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet’s disease: longitudinal study of up to 10 years. Int J Rheum Dis 17(4):444–452. https://doi.org/10.1111/1756-185X.12248

    CAS  Article  PubMed  Google Scholar 

  91. Davatchi F, Shahram F, Chams H et al (2003) The influence of the delay of aggressive treatment on the vision and its outcome in Behcet’s disease. Adv Exp Med Biol 3(528):493–494. https://doi.org/10.1007/0-306-48382-3_100

    Article  Google Scholar 

  92. Kavandi H, Khabbazi A, Kolahi S, Hajialilo M, Shayan FK, Oliaei M (2016) Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet’s disease. Clin Rheumatol 35(11):2765–2769. https://doi.org/10.1007/s10067-016-3318-6

    Article  PubMed  Google Scholar 

  93. Khabbazi A, Karkon Shayan F, Ghojazadeh M et al (2018) Adherence to treatment in patients with Behcet’s disease. Int J Rheum Dis 21(12):2158–2166. https://doi.org/10.1111/1756-185X.13109

    Article  PubMed  Google Scholar 

  94. Ebadi N, Shakoori A, Razipour M et al (2017) The spectrum of familial Mediterranean fever gene (MEFV) mutations and genotypes in Iran, and report of a novel missense variant (R204H). Eur J Med Genet 60(12):701–705. https://doi.org/10.1016/j.ejmg.2017.09.007

    Article  PubMed  Google Scholar 

  95. Salehzadeh F (2015) Familial Mediterranean fever in Iran: a report from FMF Registration Center. Int J Rheumatol 2015:912137. https://doi.org/10.1155/2015/912137

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  96. Bagheri M, Rad IA (2017) Analysis of the most common three MEFV mutations in 630 patients with familial Mediterranean fever in Iranian Azeri Turkish Population. Maedica (Buchar) 12(3):169–173

    Google Scholar 

  97. Nobakht H, Zamani F, Ajdarkosh H, Mohamadzadeh Z, Fereshtehnejad S, Nassaji M (2011) Adult-onset familial mediterranean Fever in northwestern Iran; clinical feature and treatment outcome. Middle East J Dig Dis 3(1):50–55

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Mohammadnejad L, Farajnia S (2013) Mediterranean Fever gene analysis in the Azeri Turk population with familial Mediterranean fever: evidence for new mutations associated with disease. Cell J 15(2):152–159

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Khabbazi A, Pooraliakbari A, Hajialiloo M, Kolahi S, Sharif S (2011) Study of demographic, clinical and laboratory characteristics of palindromic rheumatism and its frequency in comparison with other inflammatory arthritis in North West of Iran. Med J Tabriz Univ Med Sci 33(2):32–36

    Google Scholar 

  100. Khabbazi A, Hajialiloo M, Kolahi S, Soroosh M, Esalatmanesh K, Sharif S (2012) A multicenter study of clinical and laboratory findings of palindromic rheumatism in Iran. Int J Rheum Dis 15(4):427–430. https://doi.org/10.1111/j.1756-185x.2012.01739.x

    Article  PubMed  Google Scholar 

  101. Khabbazi A, Mirza-Aghazadeh-Attari M, Goli MT, Mahdavi AM, Hajialilo M, Rashtchizadeh N (2019) Is palindromic rheumatism a pre-rheumatoid arthritis condition? Low incidence of rheumatoid arthritis in palindromic rheumatism patients treated with tight control strategy. Rheumatol Clin 1:1. https://doi.org/10.1016/j.reuma.2019.01.002

    Article  Google Scholar 

  102. CINNAGEN. About us. https://www.cinnagen.com/Timeline.aspx?l=3#. Last updated 7 Apr 2019. Accessed 10 May 2019

  103. ARYOGEN. About us. http://www.aryogen.com/FA/index.html. Last updated 7 Feb 2019. Accessed 10 May 2019

  104. Jamshidi A, Gharibdoost F, Vojdanian M et al (2017) A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther 19(1):168. https://doi.org/10.1186/s13075-017-1371-4

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  105. Tabatabaei-Malazy O, Norani M, Heshmat R, Qorbani M et al (2018) Efficacy and safety of the biosimilar recombinant human parathyroid hormone Cinnopar® in postmenopausal osteoporotic women: a randomized double-blind clinical trial. Iran J Public Health 47(9):1336–1344

    PubMed  PubMed Central  Google Scholar 

  106. Toogeh G, Faranoush M, Razavi SM et al (2018) A double-blind, randomized comparison study between Zytux™ vs MabThera® in treatment of CLL with FCR regimen: non-inferiority clinical trial. Int J Hematol Oncol Stem Cell Res 12(2):84–91

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr. L. Khabbazi for editing this manuscript.

Author information

Affiliations

  1. Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, University Street, Tabriz, Iran

    Alireza Khabbazi

  2. Rheumatology Section, Department of Internal Medicine, AJA University of Medical Sciences, Tehran, Iran

    Mohsen Soroosh

Authors
  1. Alireza Khabbazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohsen Soroosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AK: conception and design, drafting of the manuscript, data collection, and approval of the final version. MS: data collection and critical revision of the manuscript for important intellectual content.

Corresponding author

Correspondence to Alireza Khabbazi.

Ethics declarations

Conflict of interest

None of the authors of this paper have a conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Khabbazi, A., Soroosh, M. Rheumatology training and research in Iran. Rheumatol Int 39, 1307–1319 (2019). https://doi.org/10.1007/s00296-019-04325-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-019-04325-5

Keywords

  • Arthritis
  • Rheumatology
  • Iran
  • Teaching
  • Research
  • Publications